Safety and tolerability of omalizumab in children with allergic (IgE-mediated) asthma

Abstract Objective: This pooled analysis assessed the safety of omalizumab in children with allergic (immunoglobulin E-mediated) asthma. Study design: Two double-blind, placebo-controlled studies in children (6 to

Saved in:
Bibliographic Details
Published in:Current medical research and opinion 2011-01, Vol.27 (1), p.163-169
Main Authors: Milgrom, Henry, Fowler-Taylor, Angel, Vidaurre, Carlos Fernandez, Jayawardene, Sumedha
Format: Article
Language:English
Subjects:
Algorithms
Anti-Asthmatic Agents - adverse effects
Anti-Asthmatic Agents - therapeutic use
Antibodies, Anti-Idiotypic
Antibodies, Monoclonal - adverse effects
Antibodies, Monoclonal - therapeutic use
Antibodies, Monoclonal, Humanized
Asthma
Asthma - drug therapy
Asthma - etiology
Asthma - immunology
Child
Double-Blind Method
Drug-Related Side Effects and Adverse Reactions - epidemiology
Female
Humans
IgE
Immunoglobulin E - adverse effects
Male
Omalizumab
Pediatric
Placebos
Randomized Controlled Trials as Topic - statistics & numerical data
Safety
Severity of Illness Index
Tolerability
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Objective: This pooled analysis assessed the safety of omalizumab in children with allergic (immunoglobulin E-mediated) asthma. Study design: Two double-blind, placebo-controlled studies in children (6 to
ISSN:0300-7995
1473-4877
DOI:10.1185/03007995.2010.539502